Scandinavian Biopharma Announces Publication of ETVAX® Phase 2b Data in The Lancet Infectious Diseases and Confirms Phase 3 Readiness
Scandinavian Biopharma today announces that the comprehensive results from its Phase 2b trial of ETVAX®, the lead oral vaccine candidate against enterotoxigenic Escherichia coli (ETEC), have been published in The Lancet Infectious Diseases. ETVAX® is considered Phase 3 ready for the prevention of moderate-to-severe ETEC diarrhoea in infants and young children in low- and middle-income countries.